Cost-Effectiveness of Icosapent Ethyl for Ischemic Cardiovascular Events
-
Hamid Pourasghari
,
Peyman Saberian
,
Samad Azari
,
Negar Omidi
,
Jalal Arabloo
,
Soheila Rajaie
,
Mohammad Ali Rezaei
,
Masoud Behzadifar
,
Masih Tajdini
Abstract
Background: Icosapent ethyl (IPE) has demonstrated efficacy and safety in reducing the risk of ischemic cardiovascular disease. This study aimed to systematically gather and synthesize existing cost-effectiveness analyses of IPE combined with statin therapy for cardiovascular risk reduction in primary and secondary prevention settings.
Methods: Comprehensive electronic searches were conducted across PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the NHS Economic Evaluation Database (NHS EED), and the Health Technology Assessment (HTA) database to identify relevant literature (up to May 2024). From an initial pool of 580 studies, 11 met the predefined inclusion criteria.
Results: The findings demonstrated that IPE significantly decreased hospitalization and mortality rates compared to standard treatments. The study indicated that IPE provided greater quality-adjusted life years and life-years gained than statin therapy alone. However, IPE is more expensive than conventional medications, such as statins. For instance, the 1-year cost of IPE is $3768 in Australia and $3497 in the United States per patient. Additionally, the results revealed that the threshold for assessing the effectiveness of IPE ranged from $50,000 to $150,000 in the United States and AUD 50,000 ($39,000) in Australia.
Conclusion: Based on the current study, IPE is cost-effective, with a higher probability of cost-effectiveness in patients undergoing secondary prevention than those in primary prevention.
2. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. 2020;396(10258):1204-22.
3. Ollendorf D, McQueen R, Fazioli KJIfC, Review E. Additive therapies for cardiovascular disease: effectiveness and value. 2019.
4. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2019 update a report from the American Heart Association. Circulation. 2019.
5. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. 2019;380(1):11-22.
6. Virani SS, Akeroyd JM, Ramsey DJ, Chan WJ, Frazier L, Nasir K, et al. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: implications for care under the Affordable Care Act. 2016;181:74-82.
7. Philip S, Chowdhury S, Nelson JR, Benjamin Everett P, Hulme-Lowe CK, Schmier JKJJome. A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. 2016;19(10):1003-10.
8. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease secondary prevention analysis from JELIS. 2009;73(7):1283-90.
9. Gao L, Moodie M, Li S-C. The cost-effectiveness of omega-3 polyunsaturated fatty acids–The Australian healthcare perspective. European journal of internal medicine. 2019;67:70-6.
10. Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, et al. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl–intervention trial. 2017;40(3):138-48.
11. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. 2007;369(9567):1090-8.
12. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22.
13. Fares H, Lavie CJ, DiNicolantonio JJ, O’Keefe JH, Milani RVJT, management cr. Icosapent ethyl for the treatment of severe hypertriglyceridemia. 2014;10:485.
14. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. 2013;16(2):231-50.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, medicine PGJP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. 2009;6(7):e1000097.
16. Weintraub WS, Bhatt D, Zhang Z, Zhang C, Sarahfaye D, Boden WE, et al. Cost-effectiveness of icosapent ethyl in US REDUCE-IT patients. 2020;75(11_Supplement_1):1914-.
17. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, et al. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Network Open. 2022;5(2):e2148172-e.
18. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, et al. Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States. Journal of the American Heart Association. 2024;13(1):e032413.
19. Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. European Journal of Preventive Cardiology. 2020:2047487319896648.
20. Michaeli DT, Michaeli JC, Boch T, Michaeli T. Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany. Cardiovascular drugs and therapy. 2023;37(4):683-94.
21. Michaeli DT, Michaeli JC, Boch T, Michaeli T. Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with statins compared to statin monotherapy. Clinical Drug Investigation. 2022;42(8):643-56.
22. Lachaine J, Charron J-N, Gregoire JC, Hegele RA, Leiter LA. Cost-Effectiveness of icosapent ethyl (IPE) for the reduction of the risk of ischemic cardiovascular events in Canada. ClinicoEconomics and Outcomes Research. 2023:295-308.
23. Kodera S, Morita H, Kiyosue A, Ando J, Komuro IJCJ. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia―An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS)―. 2018;82(4):1076-82.
| Files | ||
| Issue | Vol 19 No S1 (2024): Supplementary 1 | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jthc.v19is1.18478 | |
| Keywords | ||
| cost-effectiveness Icosapent Ethyl statins cardiovascular disease systematic review | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
